ERBB2 and breast carcinoma: Presently, four HER2-targeted therapies are approved by the Food and Drug Administration (FDA) for treatment of HER2-positive breast cancer: Trastuzumab®, Lapatinib®, Pertuzumab®, and Trastuzumab emtasine®.